Trade Veracyte Inc - VCYT CFD

Trading Conditions

• Spread: 0.07
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 19.46
• Open: 19.16
• 1-Year Change: -12.95%
• Day's Range: 19.16 - 19.7

Veracyte Inc Company profile

About Veracyte Inc

Veracyte, Inc. is a genomic diagnostics company. The Company offers customized biomarker testing and analytical services. It offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. It offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. It also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Veracyte Inc revenues increased 87% to $219.5M. Net loss increased from $34.9M to $75.6M. Revenues reflect United States segment increase of 83% to $201M, International segment increase from $7.9M to $18.5M. Higher net loss reflects Selling and marketing - Balancing value increase of 54% to $75.4M (expense), General & Administrative Expenses increase of 47% to $42.2M (expense).

Equity composition

Common Stock, $0.001 Par, 10/13, 125M auth., 20,989,890 issd., Insiders Own 76.17%